Oncolytic virus expressing an immune cell engager for tumor targeting
AssigneeVirogin Biotech Canada Ltd
InventorsXiaohu Liu, I-Fang Lee, Yanal M. Murad
Life of this patent
Estimating the term…
Abstract
An HSV vector with an expression cassette encoding an immune cell engager protein under control of an EF1α promoter. ICP27 under control of a CEA promoter. ICP34.5 under control of miRNA-124/143, and ICP47 under control of a ICP27 promoter is disclosed. The HSV vector also includes deletion of one copy of terminal repeat long region and one copy of terminal repeat short region. The immune cell engager protein comprises a T-cell binding domain and a tumor-associated antigen binding domain.
Claims38
A recombinant herpes simplex virus comprising a modified oncolytic herpes virus genome, wherein the modified herpes virus genome comprises an expression cassette encoding an immune cell engager protein, wherein the immune cell engager protein comprises a T-cell binding domain and a tumor-associated antigen binding domain, wherein the T-cell binding domain comprises an anti-CD3, anti-CD28, anti-OX40, or anti-4-1BB antibody or antibody fragment thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An immune cell engager protein comprising a T-cell binding domain and a tumor-associated antigen binding domain, wherein said tumor-associated antigen binding domain is anti-CEACAM6, anti-Muc16, anti-PD-L1, or anti-TfR1, wherein said T-Cell binding domain is an anti-CD3, anti-CD28, anti-OX40, or an anti-4-1BB antibody or antibody fragment.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.